SCI时时刷

search
+
Early stage gastric adenocarcinoma: clinical and molecular landscapes
Early stage gastric adenocarcinoma: clinical and molecular landscapes
Gastric adenocarcinoma, even when diagnosed at an early (localized) disease stage, poses a major health-care burden with c...
Circulating tumour cells for early detection of clinically relevant cancer
Circulating tumour cells for early detection of clinically relevant cancer
Given that cancer mortality is usually a result of late diagnosis, efforts in the field of early detection are paramount t...
The FDA’s latest draft guidance on accelerated approvals — one step forward, two steps back?
The FDA Accelerated Approval pathway, which has been pivotal in enabling early access to new oncology drugs over the past ...
Newly diagnosed AML: quizartinib improves OS
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obta...
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL
Patients with chronic lymphocytic leukaemia (CLL) typically receive first-line chemoimmunotherapy comprising the anti-CD20...
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
Despite the importance of chemotherapy-associated adverse events in oncology practice and the broad range of interventions...
The roles and implications of RNA m6A modification in cancer
The roles and implications of RNA m6A modification in cancer
N6-Methyladenosine (m6A), the most prevalent internal modification in eukaryotic mRNA, has been extensively and increasing...
SUNLIGHT illuminates the activity of bevacizumab
Patients with metastatic colorectal cancer (CRC) with disease progression on first-line 5-fluorouracil-based chemotherapy ...
ROAR brings in a new histology-agnostic approval for rare cancers
ROAR brings in a new histology-agnostic approval for rare cancers
BRAFV600E, the most common BRAF mutation, can be detected in a variety of malignancies. These include several rare cancer ...
Blinatumomab improves outcomes in infant ALL
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obta...
Gut microbiota in colorectal cancer development and therapy
Gut microbiota in colorectal cancer development and therapy
Colorectal cancer (CRC) is one of the commonest cancers globally. A unique aspect of CRC is its intimate association with ...
T-DXd is effective after T-DM1
The antibody–drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) is a highly effective second-line therapy for patients wi...
Determinants of response and resistance to T cell-engaging therapies in multiple myeloma
Determinants of response and resistance to T cell-engaging therapies in multiple myeloma
Bispecific T cell engagers offer a novel treatment approach for patients with multiple myeloma, although mechanisms of res...
National value-based pricing negotiation for oncology drugs — lessons from China
National value-based pricing negotiation for oncology drugs — lessons from China
Between 2016 and 2022, 83 previously approved oncology drugs were covered and reimbursed in China through a value-based pr...
Cholangiocarcinoma — novel biological insights and therapeutic strategies
Cholangiocarcinoma — novel biological insights and therapeutic strategies
In the past 5 years, important advances have been made in the scientific understanding and clinical management of cholangi...
Zolbetuximab moves into the SPOTLIGHT
Patients with HER2– advanced-stage gastric or gastro-oesophageal junction (G/GEJ) cancers typically receive 5-fluorouracil...
HSCT prolongs remission of high-risk CTCLs
Evidence indicates that patients with advanced-stage cutaneous T cell lymphomas (CTCLs) might benefit from allogeneic haem...
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Neoadjuvant immune-checkpoint inhibition is a promising emerging treatment approach for patients with surgically resectabl...
From AACR 2023
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obta...
Biliary tract cancer: frontline pembrolizumab hits KEYNOTE
Conventional chemotherapy for advanced-stage biliary tract cancers (BTCs) is associated with median overall survival (OS) ...
CAR T cells induce durable remission of neuroblastoma
Neuroblastoma accounts for >10% of all cancer-related deaths in the paediatric population. Among patients with relapse ...
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours
Antibody–drug conjugates (ADCs), a class of targeted cancer therapeutics combining monoclonal antibodies with a cyto...
Improving outcomes in patients with oesophageal cancer
Improving outcomes in patients with oesophageal cancer
The care of patients with oesophageal cancer or of individuals who have an elevated risk of oesophageal cancer has changed...
New combination therapy for advanced-stage RCC
Anti-PD-(L)1 antibodies in combination with a VEGF tyrosine-kinase inhibitor (TKI) or ipilimumab are the standard-of-care ...
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?
Recent FDA reviews of cemiplimab and sintilimab combined with chemotherapy for patients with advanced-stage non-small-cell...
Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis
Immune-checkpoint-inhibitor-associated myocarditis has a high fatality rate, warranting the development of more-effective ...
Envisioning trans-inclusive and trans-specific cancer care
Transgender patients are a marginalized group for whom current standards of oncology have yet to be optimized. In this Com...
Long-term outcomes following CAR T cell therapy: what we know so far
Long-term outcomes following CAR T cell therapy: what we know so far
Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells to antigens expressed on cancer...
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer
In February and March 2023, the FDA approved the immune-checkpoint inhibitors (ICIs) dostarlimab and pembrolizumab, respec...
Menin–KMT2A interaction inhibitor shows promise
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obta...
阅读更多
format_indent_increase